Skip to content

The protective effects of hydroxyapatite agarose gel on the anti-resorptive-related osteonecrosis of the jaw

The protective effects of hydroxyapatite agarose gel on the anti-resorptive-related osteonecrosis of the jaw - The effects of hydroxyapatite agarose gel on the anti-resorptive-related osteonecrosis of the jaw

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032091
Enrollment
40
Registered
2018-04-09
Start date
2018-04-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medication-related osteonecrosis of the jaws

Interventions

Medication-related osteonecrosis(MRONJ) is maxillary and mandibular osteonecrosis related not only to bisphosphonates but also to other antiresorptive agents such as denosumab and antiangiogenic drugs

Sponsors

Miyakonojo National Hospital Department of Oral and Maxillofacial Surgery
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Stage 2 and 3 of medication-related osteonecrosis of the jaws

Exclusion criteria

Exclusion criteria: Patients with a history of either radiation therapy to the head and neck region or neoplasms (including metastasis) involving the head and neck region are excluded.

Design outcomes

Primary

MeasureTime frame
Radiographic evaluation is performed at 6 and 12-months after surgery. Osteolysis, cortical bone erosion, bone sclerosis focal and diffuse sclerosis, bone sequestration, thickening of the lamina dura, persisting alveolar sockets, and the presence of pathological fracture.

Secondary

MeasureTime frame
Comprehensive oral examination is preformed. The outcome is classified into one of the following three categories; healing, improvement, unchanged, and exacerbation.

Countries

Japan

Contacts

Public Contactmasashi TABATA

Miyakonojo National Hospital Department of Oral and Maxillofacial Surgery

tabatam@mac.com0986234111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026